Unlike natural cannabinoids which belong to the 6aR - trans series, the syn
thetic dexanabinol (HU-211), a 6aS-trans enantiomer, does not have affinity
toward cannabinoid receptors and is devoid of cannabimimetic activity. On
the other hand, dexanabinol demonstrated significant neuroprotective proper
ties which prompted its development as a therapeutic agent. We now present
the extension of a series of 6aS-trans cannabinoids with novel derivatives,
including water soluble derivatives and congeners of dexanabinol.